Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

26
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
26
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

41
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
41
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

32
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
32
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

43
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
43
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

34
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
34

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Science translational medicine·2026
Same author

Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.

Neurology·2026
Same author

Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.

European journal of heart failure·2026
Same author

Racial and Ethnic Differences in Predicted Cardiovascular Disease Risk Using the PREVENT Equations in the US Population.

Circulation. Population health and outcomes·2026
Same author

Comparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals.

European heart journal. Quality of care & clinical outcomes·2026

相关实验视频

Updated: Aug 17, 2025

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.0K

社区中老年人心脏病的阶段:社区中的动脉样硬化风险研究

Khaled Shelbaya1, Brian Claggett1, Pranav Dorbala1

  • 1Brigham and Women's Hospital, Boston, MA (K.S., B.C., P.D., H.S., S.D.S., A.M.S.).

Circulation
|December 16, 2022
PubMed
概括

临床下心脏病 (VHD) 在老年人中很常见,并与心血管事件的风险增加有关. 在过去六年中, 大发体育取得了显著进展, 这表明需要采取措施减缓其发展.

关键词:
年龄的队列研究心声检查作为主题的指南心脏膜疾病

更多相关视频

Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging
06:08

Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging

Published on: February 7, 2014

17.2K
Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.1K

相关实验视频

Last Updated: Aug 17, 2025

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.0K
Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging
06:08

Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging

Published on: February 7, 2014

17.2K
Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.1K

科学领域:

  • 心脏病学
  • 老年学
  • 流行病学

背景情况:

  • 美国心脏病学会/美国心脏协会 (ACC/AHA) 关于老年人膜心脏病 (VHD) 阶段的患病率,进展和心血管疾病相关性数据有限.
  • 了解这些因素对于公共卫生倡议和老龄化人口的临床管理至关重要.

研究的目的:

  • 在老年人群中确定VHD阶段的流行和进展.
  • 评估VHD阶段与发生心血管疾病和死亡率之间的关联.
  • 在六年内评估VHD患病率的纵向变化.

主要方法:

  • 使用了来自社区动脉样硬化风险研究 (ARIC) 的数据,这是一个基于社区的前性队列.
  • 在两个时间点 (2011-2013年和2018-2019年) 使用协议心声学评估VHD阶段 (大动脉狭窄,大动脉吐,心肌狭窄,心肌吐).
  • 使用Cox比例危险模型来分析VHD阶段与发生心血管事件之间的关联,并调整多个共变量. 在纵向分析中使用了反向磨损概率权重.

主要成果:

  • 在6118名参与者 (平均年龄76岁) 中,A阶段VHD存在于39%,B阶段在17%,C/D阶段在1.1%.
  • 在VHD阶段 (A,B,C/ D) 与全因死亡,心力衰竭,心房动和冠心病的风险增加之间发现了分级关联.
  • 在大约6. 6年内,严重VHD (C/ D阶段) 的患病率从1%增加到7%,而不患VHD的患病率从43%降低到24%.

结论:

  • 临床前和进展性心脏病 (VHD) 在老年人中普遍存在,并且独立地与心血管事件的风险增加有关.
  • 在晚年,VHD阶段在六年内明显进展,严重的VHD显著增加.
  • 这些发现突显了开发措施以缓解老年人群VHD进展的重要性.